The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for ...

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

The approval gives Ascendis a window of opportunity to eat into BioMarin's market share, as the latter works on its own ...

The FDA has approved navepegritide (Yuviwel), developed by Ascendis Pharma, for children aged 2 years and older with achondroplasia, the most common form of dwarfism. Navepegritide is a prodrug ...

Oral infigratinib achieved the highest growth velocity reported to date in a randomized achondroplasia trial, growing 2.10 cm ...

Yuviwel will compete with BioMarin’s Voxzogo. Meanwhile, BridgeBio is working to bring its own achondroplasia drug, the FGFR3 blocker infigratinib, to the market.

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial ...

By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...

BioMarin Pharmaceutical researchers have created a controversial drug that helps regulate bone development in children with the most common type... Controversial Dwarfism Drug Helps Regulate Bone ...

Ascendis Pharma A/S’ Yuviwel (navepegritide) gained U.S. FDA accelerated approval Feb. 27 for children 2 and older with the rare genetic bone growth disorder achondroplasia, also known as dwarfism, wi ...

SA family fights for five-year-old Frederick’s access to rare growth therapy, highlighting treatment barriers and costs.